Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 Sep;53(3):509-12.
doi: 10.1002/pbc.21976.

Initial Testing of Aplidin by the Pediatric Pre-Clinical Testing Program

Affiliations
Free PMC article

Initial Testing of Aplidin by the Pediatric Pre-Clinical Testing Program

Christopher L Morton et al. Pediatr Blood Cancer. .
Free PMC article

Abstract

Aplidin was tested in vitro at concentrations ranging from from 0.1 nM to 1.0 microM and in vivo at a dose of 0.6 mg/kg administered intraperitoneally on an every 4 days x 3-schedule that was repeated at day 21. In vitro, Aplidin was most active against acute lymphoblastic leukemia (ALL) cell lines. In vivo, Aplidin induced significant differences in EFS distribution in 12 of 28 (43%) solid tumor models and 2 of 6 evaluable ALL models. Aplidin showed potent in vitro activity and induced significant in vivo tumor growth inhibition in some xenografts, but did not induce tumor regressions.

Similar articles

See all similar articles

Cited by 4 articles

Publication types

Feedback